West Pharmaceutical Services, Inc. WST
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.40B | 3.33B | 3.22B | 3.07B | 3.02B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.40B | 3.33B | 3.22B | 3.07B | 3.02B |
| Cost of Revenue | 2.12B | 2.10B | 2.05B | 1.97B | 1.94B |
| Gross Profit | 1.28B | 1.22B | 1.17B | 1.10B | 1.07B |
| SG&A Expenses | 427.80M | 420.10M | 402.60M | 389.70M | 365.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.90M | 0.00 | -1.20M | 1.30M | 900.00K |
| Total Operating Expenses | 2.62B | 2.60B | 2.53B | 2.44B | 2.38B |
| Operating Income | 775.40M | 729.30M | 693.30M | 638.70M | 636.30M |
| Income Before Tax | 807.10M | 709.10M | 684.90M | 615.30M | 616.80M |
| Income Tax Expenses | 168.20M | 144.20M | 142.20M | 121.60M | 125.10M |
| Earnings from Continuing Operations | 638.90 | 564.90 | 542.70 | 493.70 | 491.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 638.90M | 564.90M | 542.70M | 493.70M | 491.70M |
| EBIT | 775.40M | 729.30M | 693.30M | 638.70M | 636.30M |
| EBITDA | 959.70M | 910.70M | 869.90M | 810.10M | 801.40M |
| EPS Basic | 8.97 | 7.87 | 7.52 | 6.83 | 6.79 |
| Normalized Basic EPS | 6.98 | 6.53 | 6.20 | 5.72 | 5.68 |
| EPS Diluted | 8.91 | 7.81 | 7.48 | 6.79 | 6.75 |
| Normalized Diluted EPS | 6.94 | 6.49 | 6.17 | 5.69 | 5.64 |
| Average Basic Shares Outstanding | 285.50M | 287.30M | 288.70M | 289.20M | 289.60M |
| Average Diluted Shares Outstanding | 287.20M | 289.00M | 290.20M | 290.80M | 291.40M |
| Dividend Per Share | 0.88 | 0.87 | 0.86 | 0.85 | 0.84 |
| Payout Ratio | 9.83% | 11.05% | 11.39% | 12.40% | 12.34% |